Ono, Kyowa, BMS partner in immunotherapy combos
This article was originally published in Scrip
Executive Summary
The efficacy promise presented by combinations of new cancer immunotherapies was a major factor behind Pfizer's recent huge alliance with Merck KGaA. On a smaller scale, it is now the driving force behind a new planned clinical study in Japan with Ono Pharmaceutical and Bristol-Myers Squibb's first-in-class PD-1 immune checkpoint inhibitor.